Daud A - Search Results

1

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.

Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H. Niu G, et al. Among authors: daud a. Oncogene. 2002 Oct 10;21(46):7001-10. doi: 10.1038/sj.onc.1205859. Oncogene. 2002. PMID: 12370822

2

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.

Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Marchion DC, et al. J Cell Biochem. 2004 May 15;92(2):223-37. doi: 10.1002/jcb.20045. J Cell Biochem. 2004. PMID: 15108350

3

Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root.

Naing A, Messina JL, Vrionis FR, Daud AI. Naing A, et al. Among authors: daud ai. J Clin Oncol. 2004 Aug 1;22(15):3194-5. doi: 10.1200/JCO.2004.09.021. J Clin Oncol. 2004. PMID: 15284274 No abstract available.

4

Immunotherapy as part of a multidisciplinary approach to melanoma treatment.

Riker AI, Jove R, Daud AI. Riker AI, et al. Front Biosci. 2006 Jan 1;11:1-14. doi: 10.2741/1775. Front Biosci. 2006. PMID: 16146709 Review.

5

Cutaneous melanoma: prognostic factors.

Homsi J, Kashani-Sabet M, Messina JL, Daud A. Homsi J, et al. Among authors: daud a. Cancer Control. 2005 Oct;12(4):223-9. doi: 10.1177/107327480501200403. Cancer Control. 2005. PMID: 16258493 Review.

6

Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.

Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Clin Cancer Res. 2005 Dec 1;11(23):8467-75. doi: 10.1158/1078-0432.CCR-05-1073. Clin Cancer Res. 2005. PMID: 16322310

7

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Mol Cancer Ther. 2005 Dec;4(12):1993-2000. doi: 10.1158/1535-7163.MCT-05-0194. Mol Cancer Ther. 2005. PMID: 16373714

8

Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model.

Heller L, Merkler K, Westover J, Cruz Y, Coppola D, Benson K, Daud A, Heller R. Heller L, et al. Among authors: daud a. Clin Cancer Res. 2006 May 15;12(10):3177-83. doi: 10.1158/1078-0432.CCR-05-2727. Clin Cancer Res. 2006. PMID: 16707618

9

Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.

Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI. Khan MA, et al. Cancer Control. 2006 Jul;13(3):211-7. doi: 10.1177/107327480601300308. Cancer Control. 2006. PMID: 16885917

10

The Src signaling pathway: a potential target in melanoma and other malignancies.

Homsi J, Cubitt C, Daud A. Homsi J, et al. Among authors: daud a. Expert Opin Ther Targets. 2007 Jan;11(1):91-100. doi: 10.1517/14728222.11.1.91. Expert Opin Ther Targets. 2007. PMID: 17150037 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results